ALTAMIRA THERAPEUTICS LTD (CYTO) Stock Price & Overview
NASDAQ:CYTO • BMG0360L1349
Current stock price
The current stock price of CYTO is 0.3 USD. Today CYTO is down by -25.94%. In the past month the price decreased by -31.8%. In the past year, price decreased by -89.47%.
CYTO Key Statistics
- Market Cap
- 1.134M
- P/E
- 0.36
- Fwd P/E
- N/A
- EPS (TTM)
- 0.83
- Dividend Yield
- N/A
CYTO Stock Performance
CYTO Stock Chart
CYTO Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CYTO. When comparing the yearly performance of all stocks, CYTO is a bad performer in the overall market: 98.87% of all stocks are doing better.
CYTO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CYTO. CYTO has a bad profitability rating. Also its financial health evaluation is rather negative.
CYTO Earnings
CYTO Forecast & Estimates
7 analysts have analysed CYTO and the average price target is 5.41 USD. This implies a price increase of 1702% is expected in the next year compared to the current price of 0.3.
For the next year, analysts expect an EPS growth of -88.67% and a revenue growth -100% for CYTO
CYTO Groups
Sector & Classification
CYTO Financial Highlights
Over the last trailing twelve months CYTO reported a non-GAAP Earnings per Share(EPS) of 0.83. The EPS increased by 101.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.09% | ||
| ROE | -0.11% | ||
| Debt/Equity | 0.05 |
CYTO Ownership
CYTO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 27.29 | 900.456B | ||
| JNJ | JOHNSON & JOHNSON | 21.18 | 587.99B | ||
| MRK | MERCK & CO. INC. | 23.41 | 298.764B | ||
| PFE | PFIZER INC | 9.61 | 162.403B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.53 | 125.711B | ||
| ZTS | ZOETIS INC | 16.45 | 49.512B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.42 | 27.972B | ||
| VTRS | VIATRIS INC | 5.36 | 15.693B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.31 | 11.495B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.787B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.274B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.606B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.51 | 4.465B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CYTO
Company Profile
Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. The firm has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.
Company Info
IPO: 2014-08-06
ALTAMIRA THERAPEUTICS LTD
Clarendon House, 2 Church Street
Hamilton ZUG BM
CEO: Thomas Meyer
Employees: 10
Phone: 410417297194
ALTAMIRA THERAPEUTICS LTD / CYTO FAQ
What does CYTO do?
Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. The firm has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.
Can you provide the latest stock price for ALTAMIRA THERAPEUTICS LTD?
The current stock price of CYTO is 0.3 USD. The price decreased by -25.94% in the last trading session.
What is the dividend status of ALTAMIRA THERAPEUTICS LTD?
CYTO does not pay a dividend.
What is the ChartMill technical and fundamental rating of CYTO stock?
CYTO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for CYTO stock?
The Revenue of ALTAMIRA THERAPEUTICS LTD (CYTO) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does ALTAMIRA THERAPEUTICS LTD have?
ALTAMIRA THERAPEUTICS LTD (CYTO) currently has 10 employees.